Legacy Healthcare
Legacy Healthcare is developing treatments for autoimmune diseases. Its first drug, Cinainu, demonstrated efficacy and safety in a Ph 2/3 trial in children and adolescents with Alopecia Areata. Cinainu is a first-in-class botanical drug with patent protection until 2043. Thanks to unparallel safety and efficacy, physicians say Cinainu would be their first-line treatment in a market expected to generate $5b by 2030. The company is raising funds to pursue FDA track.
Date, time and room information
May 5, 16:15 - 16:30, room Montreal
Category
Clinical stage development company
Title of the presentation
First-in-class treatment for Alopecia Areata with positive Phase 2/3 data
Speaker information
| Name | Position | Institution |
|---|---|---|
| Saad HARTI | CEO | Legacy Healthcare |
Host and event manager:
Logistics and marketing partner:
